EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Effects of Bifidobacterium-based interventions on patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized clinical trials

Hongkai Chang, Huixin Song, Lubo Shi, Peng Li

Digestive Diseases · 05.11.2026

DOI: 10.1159/ddi/acnag015 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Digestive Diseases, online erschienen am 05.11.2026. Verfasst von Hongkai Chang und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bifidobacterium has showcased potential benefits in managing irritable bowel syndrome (IBS) symptoms.

Methods

We systematically searched online databases up until 1 December 2025, to identify randomized, double-blind, placebo-controlled trials investigating the efficacy of Bifidobacterium-based or Bifidobacterium-containing preparations in IBS patients. Pooled analyses of the effects of these interventions on IBS symptom relief were calculated using a random-effects model. Subgroup analyses were conducted based on different regions, doses, and treatment durations.

Results

Eight RCTs encompassing 1,304 patients were identified. Bifidobacterium-based interventions demonstrated significant improvements in overall response rate (RR: 1.99; 95% CI: 1.63–2.43; P < 0.00001), abdominal pain relief (RR: 2.09; 95% CI: 1.36–3.24; P = 0.0009), and subjective relief (RR: 1.62; 95% CI: 1.28–2.05; P < 0.0001). Significant benefits were observed in both adult (RR: 1.94; 95% CI: 1.58–2.40; P < 0.00001) and pediatric cohorts (RR: 2.86; 95% CI: 1.33–6.15; P = 0.007). However, subgroup comparisons showed comparable efficacy between daily dosages of < 10¹⁰ and ≥ 10¹⁰ CFU (P = 0.65) and between treatment durations of < 8 and ≥ 8 weeks (P = 0.33).

Conclusions

Bifidobacterium-based interventions effectively alleviate IBS symptoms, particularly abdominal pain and subjective discomfort, in both adults and children. However, current evidence does not demonstrate superiority for specific doses or extended durations, precluding definitive conclusions regarding optimal posology.

Systematic review registration

PROSPERO registration no. CRD420251252390.

Zitieren

APA

Chang, H., Song, H., Shi, L., & Li, P. (2026). Effects of Bifidobacterium-based interventions on patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized clinical trials. Digestive Diseases. https://doi.org/10.1159/ddi/acnag015

Vancouver

Chang H, Song H, Shi L, Li P. Effects of Bifidobacterium-based interventions on patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized clinical trials. Digestive Diseases. 2026. doi:10.1159/ddi/acnag015

BibTeX
@article{Chang2026,
  author = {Chang, Hongkai and Song, Huixin and Shi, Lubo and Li, Peng},
  title = {Effects of Bifidobacterium-based interventions on patients with irritable bowel syndrome: a systematic review and meta-analysis of randomized clinical trials},
  journal = {Digestive Diseases},
  year = {2026},
  doi = {10.1159/ddi/acnag015}
}
Kostenlos starten →